Early pubertal female rats are more resistant than males to 6-hydroxydopamine neurotoxicity and behavioural deficits: A possible role for trophic factors

Restorative Neurology and Neuroscience

Volumn 25, Issue 5-6, 2007, Pages 513-526

  Pienaar, I S ^a,d   Schallert, T ^b   Russell, V A ^c   Kellaway, L A ^c   Carr, J A ^a   Daniels, W M U ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

6 hydroxydopamine lesion; Behaviour; Dose related effects; Neuroprotection; Parkinson's disease; Sexual dimorphism

Indexed keywords

OXIDOPAMINE; STEROID HORMONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CONTROLLED STUDY; EVOKED RESPONSE; FEMALE; IMMUNOREACTIVITY; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MEDIAL FOREBRAIN BUNDLE; MENTAL DISORDERS; NERVE GROWTH FACTOR; NEUROTOXICITY SYNDROMES; NEUROTOXINS; OXIDOPAMINE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; TYROSINE 3-MONOOXYGENASE; VIBRISSAE;

EID: 42149161699     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Andersen, S. L. (2002). Changes in the second messenger cyclic AMP during development may underlie motoric symptoms in attention deficit/hyperactivity disorder (ADHD). Behav Brain Res, 130, 197-201.
2. Andrew, R., Watson, D. G., Best, S. A., Midgley, J. M., Wenlong, H. & Petty, R. K. H. (1993). The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem Res, 18, 1175-1177.
3. Andrews, G. K., Dziadek, M. & Tamaoki, T. (1982). Expression and methylation of the mouse alpha-fetoprotein gene in embryonic, adult, and neoplastic tissues. J Biol Chem, 257, 5148-5153.
4. Anstrom, K. K., Schallert, T., Woodlee, M. T., Shattuck, A. & Roberts, D. C. S. (2007). Repetitive vibrissae-evoked forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease. Behav Brain Res, 179, 183-191.
5. Azcoitia, I., Fernandez-Galaz, C., Sierra, A. & Garcia-Segura, L. (1999). Gonodal hormones affect neuronal vulnerability to excitotoxin-induced degeneration. J Neurocytol, 28, 699-710.
6. Bakker, J., Honda, S., Harada, N. & Balthazart, J. (2002). The aromatose knockout mouse provides new evidence that estradiol is required during development in the female for the expression of socio-sexual behaviours in adulthood. J Neurosci, 22, 9104-9112.
7. Bakker, J., De Mees, C., Douhard, Q., Balthazart, J., Gabant, P., Szpirer, J., et al. (2006). Alpha-fetoprotein protects the developing female mouse brain from masculinisation and defeminisation by estrogens. Nat Neurosci, 9, 220-226.
8. Baldereschi, M., Di Carlo, A., Vanni, P., Ghetti, A., Carbonin, P., Amaducci, L. & Inzitari, D. (2000). Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men, ILSA working group. Italian longitudinal study on ageing. Neurology, 55, 1358-1363.
9. Barroso-Chinea, P., Cruz-Muros, I., Aymerich, M. S., Rodriguez-Diaz, M., Afonso-Oramas, D., Lanciego, J. L., et al. (2005). Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci, 21, 1815-1827.
10. Barth, T. M., Grant, M. L. & Schallert, T. (1990). Effects of MK-801 on recovery from sensorimotor cortex lesions. Stroke, 21, III153-157.
11. Basagan-Mogol, E., Buyukuysal, R. L. & Korfali, G. (2005). Effects of ketamine and thiopental on ischemia reoxygenation-induced LDH leakage and amino acid release from rat striatal slices. J Neurosurg Anaesthesiol, 17, 20-26.
12. Becker, J. B. (1990). Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release. Synapse, 5, 157-164.
13. Becker, J. B. (1999). Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav, 64, 803-812.
14. Becker, J. B. & Ramirez, V. D. (1981). Experimental studies on the development of sex differences in the release of dopamine from striatal tissue fragments in vitro. Neuroendocrinology, 32, 168-172.
15. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V. & Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci, 3, 1301-1306.
16. Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R. & Verna, J. M. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol, 135, 135-172.
17. Bower, J. H., Maraganore, D. M., McDonnell, S. K. & Rocca, W. A. (1999). Incidence and distribution of parkinsonism in Omsted County, Minnesota, 1976-1990. Neurology, 52, 1214-1220.
18. Braak, H., Braak, E., Yilmazer, D., Schultz, C., de Vos, R. A. & Jansen, E. N. (1995). Nigral and extranigral pathology in Parkinson's disease. J Neural Transm, 46, 15-31.
19. Brookes, P. S., Levonen, A. L., Shiva, S., Sarti, P. & Darley-Usmar, V. M. (2002). Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med, 33, 755-764.
20. Callier, S., Morissette, M., Grandbois, M., Pelaprat, D. & Di Paulo, T. (2001). Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57B1/6 mice. Synapse, 41, 131-138.
21. Cass, W. A., Peters, L. E. & Smith, L. P. (2005). Reductions in spontaneous locomotor activity in aged male, but not female rats in a model of early Parkinson's disease. Brain Research, 1034, 153-161.
22. Castner, S. A., Xiaon, L. & Becker, J. B. (1993). Sex differences in striatal dopamine: in vivo microdialysis and behavioural studies. Brain Res, 610, 127-134.
23. Chakraborti, T., Das, S., Mondal, M., Roychoudhury, S. & Chakraborti, S. (1999). Age-dependent change in arachidonic acid metabolic capacity in rat alveolar macrophages. Cell Signalling, 11, 77-85.
24. Cohen, A. D., Tillerson, J. L., Smith, A. D., Schallert, T. & Zigmond, M. J. (2003). Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem, 85, 299-305.
25. Crowley, W. R., O'Donohue, T. L. & Jacobowitz, D. M. (1978). Sex differences in catecholamine content in discrete brain nuclei of the rat: effects of neonatal castration or testosterone treatment. Acta Endocrinol, 89, 20-28.
26. Dewing, P., Shi, T., Horvath, S. & Vilain, E. (2003). Sexually dimorphic gene expression in mouse brain precedes gonadal differentiation. Brain Res Mol Brain Res, 118, 82-90.
27. Dewing, P., Chiang, C. W. K., Sinchak, K., Sim, H., Fernagut, P.-O., Kelly, S., et al. (2006). Direct regulation of adult brain function by the male-specific factor SRY. Curr Biol, 16, 415-420.
28. Disshon, K. A., Boja, J. W. & Dluzen, D. E. (1998). Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol, 345, 207-211.
29. Dluzen, D. E. (1996). The effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system in male C57/B1 mice. Brain Res, 715, 113-119.
30. Dluzen, D. E. & McDermott, J. L. (2002). Estrogen, anti-estrogen and gender differences in metamphetamine neurotoxicity. Ann NY Acad Sci, 965, 136-156.
31. Dluzen, D. & Horstink, M. (2003). Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine, 21, 67-75.
32. Döhler, K. D., Hancke, J. L., Srivastava, S. S., Hofmann, C., Shryne, J. E. & Gorski, R. A. (1984). Participation of estrogens in female sexual differentiation of the brain; neuroanatomical, neuroendocrine and behavioural evidence. In: Sex Differences in the Brain, Progress in Brain Research, De Vries, G.J., De Bruin, J.P.C., Uylings, H.B.M. & Corner, M.A., eds, Amsterdam: Elsevier, pp. 99-117.
33. Ekue, A., Boulanger, M. J. F., Morissette, M. & Di Paolo, T. (2002). Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-mice. J Neuroendocrinol, 14, 731-736.
34. Fernandez-Ruiz, J., de Miguel, R., Hernandez, M. L., Cebeira, M. & Ramos, J. A. (1992). Comparisons between brain dopaminergic neurons of juvenile and aged rats: sex-related differences. Mech Ageing Dev, 63, 45-55.
35. Fitch, R. H. & Denenburg, V. H. (1998). A role for ovarian hormones in sexual differentiation of the brain. Behav Brain Sci, 21, 311-327.
36. Flatmark, T. & Stevens, R. C. (1999). Structural insight into the aromatic amino acid hydroylases and their disease-related mutant forms. Chem Rev, 99, 2137-2160.
37. Gabant, P. (2002). Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. Proc Natl Acad Sci USA, 99, 12865-12870.
38. Gao, X. & Dluzen, D. E. (2001). Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neurosci, 103, 385-394.
39. Garcia de Yebenes, J., Yebenes, J. & Mena, M. A. (2000). Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease. Neurotox Res, 2, 115-137.
40. Gillies, G. E., Murray, H. E., Dexter, D. & McArthur, S. (2004). Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav, 78, 513-522.
41. Glinka, Y., Gassen, M. & Youdim, M. B. (1997). Mechanisms of 6-hydroxydopamine neurotoxicity. J Neural Transm, 50, 55-66.
42. Heller, A., Bubula, N., Lew, R., Heller, B. & Won, L. (2001). Gender-dependent enhanced adult neurotoxic response to methamphetamine following fetal exposure to the drug. J Pharmacol Exp Ther, 298, 769-773.
43. Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature, 407, 770-776.
44. Hornykiewicz, O. (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev, 18, 925-964.
45. Horstink, M. W., Strijks, E. & Dluzen, D. E. (2003). Estrogen and Parkinson's disease. Adv Neurol, 91, 107-114.
46. Hynes, M. A., Poulsen, K., Armanini, M., Berkemeier, L., Phillips, H. & Rosenthal, A. (1994). Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. J Neurosci Res, 37, 144-154.
47. Jiang, O., Yan, Z. & Feng, J. (2006). Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J Biol Chem, 281(39), 29391-29400.
48. Koerner, I. P. & Brambrink, A. M. (2006). Brain protection by anaesthetic agents. Curr Opin Anaesthesiol, 19(5), 481-486.
49. Kobayashi, K. & Nagatsu, T. (2005). Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. Biochem Biophys Res Commun, 338, 267-270.
50. Knoll, J. & Miklya, I. (1995). Enhanced catecholaminergic and serotoninergic vity in rat brain from weaning to sexual maturity: rationale for prophylactic () deprenyl (selegiline) medication. Life Sci, 56, 611-620.
51. Knoll, J., Miklya, I., Knoll, B. & Dallo, J. (2000). Sexual hormones terminate in the rat: the significantly enhanced catecholaminergic/serotonergic tone in the brain characteristic to the post-weaning period. Life Sci, 67, 765-773.
52. Kuopio, A. M., Marttila, R. J., Helenius, H. & Rinne, U. K. (1999). Changing epidemiology of Parkinson's disease in south-western Finland. Neurology, 52, 302-308.
53. Li, X., Blizzard, K. K., Zeng, Z., De Vries, A. C., Hurn, P. D. & McCullough, L. D. (2004). Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol, 187, 94-104.
54. Liang, C. L., Wang, T. T., Luby-Phelps, K. & German, D. C. (2006). Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp Neurol, 203, 370-380.
55. Ling, Z. D., Collier, T. J., Sortwell, C. E., Lipton, J. W., Vu, T. Q., Robie, H. C., et al. (2000). Striatal trophic activity is reduced in the aged rat brain. Brain Res, 856, 301-309.
56. Lorigados Pedre, L., Pavon Fuentes, N., Alvarez Gonzalez, L., McRae, A., Serrano Sanchez, T., Blanco Lescano, L., et al. (2002). Nerve growth factor levels Parkinson disease and experimental parkinsonian rats. Brain Res, 952, 122-127.
57. MacLusky, N. J. & Naftolin, F. (1981). Sexual differentiation of the central nervous system. Science, 4488, 1294-1302.
58. Mattson, M. P. & Magnus, T. (2006). Ageing and neuronal vulnerability. Nat Rev Neurosci, 7, 278-294.
59. Mattson, M. P., Robinson, N. & Guo, Q. (1997). Estrogens stabilize mitochondrial function and protect neural cells against the proapoptotic action of mutant presenilin-1. NeuroReport, 8, 3817-3821.
60. Mayeux, R., Marder, K., Cote, L. J., Denaro, J., Hemenegildo, N., Mejia, H., et al. (1995). The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol, 142, 820-827.
61. McDermott, J. L., Liu, B. & Dluzen, D. E. (1994). Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol, 843, 306-311.
62. McEwen, B. S., Plapinger, L., Chapal, C., Gerlach, J. & Wallach, G. (1975). The role of fetal-neonatal estrogen binding proteins in the association of estrogen with neonatal brain cell nuclear receptors. Brain Res, 96, 400-407.
63. Milanov, I., Kmetska, K., Karakolev, B. & Nedialkov, E. (2001). Prevalence of Parkinson's disease in Bulgaria. Neuroepidemiology, 20, 212-214.
64. Miller, D. B., Ali, S. F., O'Callaghan, J. P. & Laws, S. C. (1998). The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci, 844, 153-165.
65. Moroz, I. A., Rajabi, H., Rodaros, D. & Stewart, J. (2003). Effects of sex and hormonal status on astrocytic basic fibroblast growth-factor 2 and tyrosine hydroxylase immunoreactivity after medial forebrain bundle 6-hydroxydopamine lesions of the midbrain dopamine neurons. Neuroscience, 118, 463-476.
66. Murray, H. E., Pillai, A. V., McArthur, S. R., Razvi, N., Datla, K. P., Dexter, D. T., et al. (2003). Dose and sex dependent effects of the neurotoxin 6- hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience, 116, 213-222.
67. Murphy, S. J., Traystman, R. J., Hurn, P. D. & Duckles, S. P. (2000). Progesterone exacerbates striatal stroke injury in progesterone-deficient female animals. Stroke, 31, 1173-1178.
68. Nagels, W., Demeyere, R., Van Hemelrijk, J., Vandenbussche, E., Gijbels, K. & Vandermeersch, E. (2004). Evaluation of the neuroprotective effects of S(+)-ketamine during open-heart surgery. Anaest Analg, 98, 1595-1603.
69. Nilsen, J. & Brinton, R. D. (2003). Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signalling. Proc Natl Acad Sci USA, 100, 2842-2847.
70. Olanov, C. W., Schapira, A. H. & Agid, Y. (2003). Neuroprotection for Parkinson's disease prospects and promises. Ann Neurol, 53, S1-S2.
71. Olsson, M., Nikkhah, G., Bentlage, C. & Bjorklund, A. (1995). Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci, 15, 3863-3875.
72. Pasqualini, C., Olivier, V., Guilbert, B., Frain, O. & Leviel, V. (1995). Acute stimulatory effect of estradiol on striatal dopamine synthesis. J Neurochem, 65, 1651-1657.
73. th ed). San Diego: Academic Press.
74. Payami, H. & Zareparsi, S. (1998). Genetic epidemiology of Parkinson's disease. J Geriatr Psychiatry Neurol, 11, 98-106.
75. Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., et al. (2007). Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol, 66, 75-85.
76. Raynaud, P. (1973). Influence of rat estradiol binding plasma protein (EBP) on uterotrophic activity. Steroids, 21, 249-258.
77. Reglodi, D., Lubics, A., Kiss, P., Lengvari, I., Gaszner, B., Toth, G., et al. (2006). Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides, 40, 265-274.
78. Riederer, P. & Wuketich, S. (1976). Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm, 38, 277-301.
79. Roberts, D. C., Zis, A. P. & Fibiger, H. C. (1975). Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non involvement of norepinephrine. Brain Res, 93, 441-454.
80. Roof, R. L. & Hall, E. D. (2000). Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma, 17(5), 367-388.
81. Sa, S. I. & Madeira, M. D. (2005). Estrogen modulates the sexually dimorphic synaptic connectivity of the ventromedial nucleus. J Comp Neurol, 484, 68-79.
82. Salinas, M., Diaz, R., Abraham, N. G., Ruiz de Galarreta, C. M. & Cuadrado, A. (2003). Nerve growth factor protects against 6-hydroxydopamine- induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem, 278, 1389-13904.
83. Schallert, T., De Ryck, M., Whishaw, I. Q., Ramirez, V. D. & Teitelbaum, P. (1979). Excessive bracing reactions and their control by atropine and L-dopa in an animal analog of parkinsonism. Exp Neurol, 64, 33-43.
84. Schallert, T., Norton, D. & Jones, T. A. (1992). A clinically relevant unilateral rat model of parkinsonian akinesia. J Neural Transpl Plast, 3, 332-333.
85. Schallert, T. & Tillerson, J. L. (1999). Intervention strategies for degeneration of dopamine neurons in parkisonism: optimizing behavioural assessment of outcome, in: Central Nervous System Diseases, D.F. Emerich, R.L. Dean and P.R. Sanberg, eds, Totawa: Humana Press, pp. 131-151.
86. Schrag, A., Ben-Shlomo, Y. & Quinn, N. P. (2000). Crosssectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ, 321, 21-22.
87. Schwarting, R. K. & Huston, J. P. (1996). Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurbiol, 49, 215-266.
88. Senoh, S., Creveling, C. R., Udenfriend, S. & Witkop, B. (1959). Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J Am Chem Soc, 81, 6236.
89. Shimoke, K. & Chiba, H. (2001). Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J Neurosci Res, 63, 402-409.
90. Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E. & Masliah, E. (2004). Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol, 186, 158-172.
91. Stromberg, I., Wetmore, C. J., Ebendal, T., Ernfors, P., Persson, H. & Olson, L. (1990). Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF. J Neurosci Res, 25, 405-411.
92. Sun, M., Kong, L., Wang, X., Lu, X. G., Gao, Q. & Geller, A. L. (2005). Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res, 1052, 119-129.
93. Tamas, A., Lubics, A., Szalontay, L., Lengvari, I. & Reglodi, D. (2005). Age and gender differences in behavioural and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Behav Brain Res, 15, 221-229.
94. Toran-Allerand, C. D. (1984). Onthe genesis of sexual differentiation of the central nervous system: morphogenetic consequences of steroidal exposure and possible role of a-fetoprotein, in: sex differences in the brain: the relation between structure and function, G.J. de Vries, J.P.C. De Bruin, H.B.M. Uylings and M.A. Corner, eds, Elsevier, Amsterdam, pp. 63-98.
95. Torp, R., Singh, P. B., Sorensen, D. R. & Dietrichs, E. (2006). Growth factors as neuroprotective treatment in Parkinson disease? Tidsskr Nor Laegeforen, 126, 899-901.
96. Wang, J., Green, P. S. & Simpkins, J. W. (2001). Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J Neurochem, 77, 804-811.
97. Weisz, J. & Ward, I. L. (1980). Plasma testosterone and progesterone titers of pregnant rats, their male and female fetuses and neonatal offspring. Endocrinology, 106, 306-316.
98. Woodlee, M. T., Asseo-Garcia, A. M., Zhao, X., Liu, S. J., Jones, T. A. & Schallert, T. (2005). Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp Neurol, 191, 310-317.
99. Xie, T., Ho, D. L. & Ramsden, D. (1999). Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol, 56, 31-38.
100. Yang, S.-H., Liu, R., Perez, E. J., Wen, Y., Stevens Jr., S. M., Valencia, T., et al. (2004), Mitochondrial localization of estrogen receptor β. PNAS, 101, 4130-4135.
101. Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J. W., et al. (2006). Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA, 103, 10793-10798.
102. Yu, L. & Liao, P. C. (2000). Sexual differences in and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm, 107, 419-427.
103. Zhang, Y. Q., Shi, J., Rajakumar, G., Day, A. L. & Simpkins, J. W. (1998). Effects of gender and estradiol treatment on focal brain ischemia. Brain Res, 784, 321-324.
104. Zhou, X. F. & Rush, R. A. (1996). Endogenous nerve growth factor is required for regulation of the low affinity neurotrophin receptor (p75) in sympathetic but not sensory ganglia. J Comp Neurol, 372, 37-48.